Skip to main content

Table 3 Quality of life score according to Age, Education, and Parity of the CC patients

From: Quality of life among cervical cancer patients following completion of chemoradiotherapy at Ocean Road Cancer Institute (ORCI) in Tanzania

QLQ Items

Age

P

Education

P

Parity

P

 < 52

 > 53

No formal

Formal

Para ≤ 4

Para ≥ 5

n = 164

n = 159

n = 52

n = 271

n = 167

n = 156

QLQ-C30 Functional scales

Global Health Status/QOL

63.9 ± 18.0

65.0 ± 17.3

0.454

69.5 ± 18.3

63.5 ± 17.4

0.019

65.2 ± 18.0

63.6 ± 17.3

0.300

Physical Functioning

87.2 ± 13.5

84.3 ± 15.5

0.146

87.3 ± 13.4

85.6 ± 14.8

0.629

87.8 ± 14.1

83.5 ± 14.8

0.003

Role Functioning

92.5 ± 17.3

87.7 ± 19.2

0.001

89.3 ± 21.2

90.5 ± 17.6

0.886

93.2 ± 15.3

86.9 ± 20.7

0.000

Emotional Functioning

80.2 ± 23.8

80.5 ± 21.5

0.676

85.5 ± 22.8

79.6 ± 22.1

0.022

81.0 ± 23.7

79.6 ± 21.6

0.244

Cognitive Functioning

84.2 ± 22.2

78.5 ± 25.3

0.021

83.0 ± 26.0

81.2 ± 23.4

0.482

87.1 ± 20.1

75.3 ± 26.1

0.000

Social Functioning

73.2 ± 31.1

77.6 ± 29.6

0.227

81.7 ± 28.2

74.2 ± 30.7

0.096

78.8 ± 28.4

71.6 ± 32.0

0.054

QLQ-C30 Symptom scales

Fatigue

14.5 ± 18.2

17.9 ± 19.3

0.103

17.6 ± 21.7

15.7 ± 18.1

0.582

5.3 ± 15.4

4.9 ± 14.9

0.919

Nausea & Vomiting

4.9 ± 15.4

5.3 ± 14.9

0.483

6.3 ± 18.7

4.9 ± 14.5

0.886

17.7 ± 23.1

22.1 ± 22.5

0.023

Pain

18.5 ± 23.4

21.2 ± 22.4

0.144

18.7 ± 23.5

19.9 ± 22.8

0.812

3.6 ± 12.2

4.5 ± 16.1

0.964

Dyspnea

2.8 ± 11.3

5.2 ± 16.6

0.146

6.7 ± 22.3

3.6 ± 12.2

0.789

10.0 ± 23.3

16 ± 26.9

0.019

Insomnia

9.6 ± 21.8

16.4 ± 28.0

0.023

16.0 ± 31.0

12.3 ± 24.1

0.567

7.4 ± 19.9

10.5 ± 23.3

0.152

Appetite Loss

8.6 ± 21.1

9.3 ± 22.2

0.861

8.0 ± 20.8

9.2 ± 21.9

0.593

15.8 ± 25.6

22.4 ± 29.1

0.032

Constipation

19.7 ± 26.6

18.2 ± 28.5

0.293

12.7 ± 26.0

20.0 ± 27.6

0.039

2.4 ± 10.7

5.3 ± 19.9

0.271

Diarrhea

3.0 ± 13.2

4.6 ± 18.2

0.585

5.3 ± 19.5

3.6 ± 15.2

0.754

61.7 ± 35.8

65.8 ± 37.5

0.103

Financial difficulties

64.0 ± 37.3

63.3 ± 36.0

0.981

51.3 ± 42.7

65.8 ± 35.1

0.066

5.3 ± 15.4

4.9 ± 14.9

0.919

QLQ-CX24 Symptom scales

Symptom Experience

13.8 ± 12.0

14.5 ± 11.0

0.265

12.5 ± 11.3

14.4 ± 11.5

0.215

12.8 ± 11.9

15.5 ± 10.9

0.005

Body Image

23.8 ± 28.5

15.5 ± 23.5

0.013

16.7 ± 22.6

20.2 ± 27.1

0.549

16.9 ± 25.8

22.6 ± 26.8

0.050

Sexual/Vaginal Functioning

29.9 ± 21.7

28.0 ± 24.4

0.852

36.1 ± 31.5

29.2 ± 21.8

0.542

31.6 ± 23.1

26.2 ± 20.4

0.422

Lymphoedema

6.0 ± 18.3

9.6 ± 16.9

0.004

3.9 ± 12.7

8.5 ± 18.4

0.065

5.5 ± 17.0

10.2 ± 18.0

0.001

Peripheral Neuropathy

19.0 ± 27.0

26.6 ± 30.3

0.012

21.2 ± 28.0

23.1 ± 29.1

0.799

24.0 ± 30.3

21.5 ± 27.2

0.585

Menopausal Symptoms

19.0 ± 31.9

15.6 ± 28.8

0.342

14.1 ± 25.0

17.9 ± 31.3

0.869

18.8 ± 30.4

15.7 ± 30.4

0.227

Sexual Worry

51.1 ± 42.3

39.9 ± 44.4

0.018

40.4 ± 46.4

46.6 ± 43.1

0.324

43.4 ± 43.0

48.0 ± 44.3

0.386

QLQ-CX24 Functional scales

Sexual Activity

14.3 ± 21.6

3.8 ± 14.1

0.000

2.6 ± 11.1

10.4 ± 19.9

0.324

10.8 ± 19.8

7.3 ± 17.9

0.051

Sexual Enjoyment

45.0 ± 29.2

38.5 ± 35.6

0.529

33.3 ± 0.0

44.1 ± 30.7

0.527

46.2 ± 32.3

39.7 ± 26.7

0.422

  1. Values are in mean score ± SD. Significance P < 0.005 by Mann Whitney U test and significant values are bolded